BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/27/2015 4:29:00 PM | Browse: 636 | Download: 679
Publication Name World Journal of Gastroenterology
Manuscript ID 15266
Country/Territory Belgium
2014-11-18 16:59
Peer-Review Started
2014-11-19 09:01
To Make the First Decision
2014-12-11 20:19
Return for Revision
2014-12-24 09:56
2015-01-07 04:11
Second Decision
2015-02-10 21:23
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-02-11 15:40
Articles in Press
2015-02-11 16:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-04-05 18:36
Publish the Manuscript Online
2015-04-27 16:22
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Editorial
Article Title Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease
Manuscript Source Invited Manuscript
All Author List Konstantinos Papamichael and Severine Vermeire
Funding Agency and Grant Number
Corresponding Author Konstantinos Papamichael, MD, PhD, FEBGH, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, Herestraat 49, 3000 Leuven, Belgium. konstantinos.papamichail@kuleuven.be
Key Words Inflammatory bowel disease; Anti-tumour necrosis factor α therapy; Withdrawal; Remission; Infliximab
Core Tip Anti-tumour necrosis factor α (anti-TNFα) therapy is an established treatment in inflammatory bowel disease. Although guidelines exist on initiation of anti-TNFα therapy in inflammatory bowel diseases, information on if, when, how and in whom therapy can be stopped is limited. This is nevertheless an important topic taking under consideration the cost and the possible adverse events associated with biological agents as well as the desire of patients to discontinue medication especially after a long maintained remission. Moreover, although drug discontinuation for reasons other than loss of response is very usual in real-life clinical practice, the optimal withdrawal strategy is still debated.
Publish Date 2015-04-27 16:22
Citation Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World J Gastroenterol 2015; 21(16): 4773-4778
URL http://www.wjgnet.com/1007-9327/full/v21/i16/4773.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i16.4773
Full Article (PDF) WJG-21-4773.pdf
Full Article (Word) WJG-21-4773.doc
Manuscript File 15266-Review.doc
Answering Reviewers 15266-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form 15266-Conflict-of-interest statement.pdf
Copyright License Agreement 15266-Copyright assignment.pdf
Peer-review Report 15266-Peer-review(s).pdf
Scientific Misconduct Check 15266-Scientific misconduct check.pdf
Scientific Editor Work List 15266-Scientific editor work list.pdf